Prandial subcutaneous injections of glucagon-like peptide-1 cause weight loss in obese human subjects
Research output: Contribution to journal › Journal article › Research › peer-review
Standard
Prandial subcutaneous injections of glucagon-like peptide-1 cause weight loss in obese human subjects. / Näslund, Erik; King, N; Mansten, S; Adner, N; Holst, Jens Juul; Gutniak, M; Hellström, P M.
In: The British Journal of Nutrition, Vol. 91, No. 3, 03.2004, p. 439-46.Research output: Contribution to journal › Journal article › Research › peer-review
Harvard
APA
Vancouver
Author
Bibtex
}
RIS
TY - JOUR
T1 - Prandial subcutaneous injections of glucagon-like peptide-1 cause weight loss in obese human subjects
AU - Näslund, Erik
AU - King, N
AU - Mansten, S
AU - Adner, N
AU - Holst, Jens Juul
AU - Gutniak, M
AU - Hellström, P M
PY - 2004/3
Y1 - 2004/3
N2 - Recombinant glucagon-like peptide-1 (7-36)amide (rGLP-1) was recently shown to cause significant weight loss in type 2 diabetics when administered for 6 weeks as a continuous subcutaneous infusion. The mechanisms responsible for the weight loss are not clarified. In the present study, rGLP-1 was given for 5 d by prandial subcutaneous injections (PSI) (76 nmol 30 min before meals, four times daily; a total of 302.4 nmol/24 h) or by continuous subcutaneous infusion (CSI) (12.7 nmol/h; a total of 304.8 nmol/24 h). This was performed in nineteen healthy obese subjects (mean age 44.2 (sem 2.5) years; BMI 39.0 (sem 1.2) kg/m(2)) in a prospective randomised, double-blind, placebo-controlled, cross-over study. Compared with the placebo, rGLP-1 administered as PSI and by CSI generated a 15 % reduction in mean food intake per meal (P=0.02) after 5 d treatment. A weight loss of 0.55 (sem 0.2) kg (P<0.05) was registered after 5 d with PSI of rGLP-1. Gastric emptying rate was reduced during both PSI (P<0.001) and CSI (P<0.05) treatment, but more rapidly and to a greater extent with PSI of rGLP-1. To conclude, a 5 d treatment of rGLP-1 at high doses by PSI, but not CSI, promptly slowed gastric emptying as a probable mechanism of action of increased satiety, decreased hunger and, hence, reduced food intake with an ensuing weight loss.
AB - Recombinant glucagon-like peptide-1 (7-36)amide (rGLP-1) was recently shown to cause significant weight loss in type 2 diabetics when administered for 6 weeks as a continuous subcutaneous infusion. The mechanisms responsible for the weight loss are not clarified. In the present study, rGLP-1 was given for 5 d by prandial subcutaneous injections (PSI) (76 nmol 30 min before meals, four times daily; a total of 302.4 nmol/24 h) or by continuous subcutaneous infusion (CSI) (12.7 nmol/h; a total of 304.8 nmol/24 h). This was performed in nineteen healthy obese subjects (mean age 44.2 (sem 2.5) years; BMI 39.0 (sem 1.2) kg/m(2)) in a prospective randomised, double-blind, placebo-controlled, cross-over study. Compared with the placebo, rGLP-1 administered as PSI and by CSI generated a 15 % reduction in mean food intake per meal (P=0.02) after 5 d treatment. A weight loss of 0.55 (sem 0.2) kg (P<0.05) was registered after 5 d with PSI of rGLP-1. Gastric emptying rate was reduced during both PSI (P<0.001) and CSI (P<0.05) treatment, but more rapidly and to a greater extent with PSI of rGLP-1. To conclude, a 5 d treatment of rGLP-1 at high doses by PSI, but not CSI, promptly slowed gastric emptying as a probable mechanism of action of increased satiety, decreased hunger and, hence, reduced food intake with an ensuing weight loss.
KW - Adult
KW - Cross-Over Studies
KW - Double-Blind Method
KW - Eating
KW - Feeding Behavior
KW - Female
KW - Gastric Emptying
KW - Glucagon
KW - Glucagon-Like Peptide 1
KW - Humans
KW - Hunger
KW - Infusions, Parenteral
KW - Injections, Subcutaneous
KW - Male
KW - Middle Aged
KW - Nausea
KW - Obesity
KW - Peptide Fragments
KW - Protein Precursors
KW - Recombinant Proteins
KW - Satiation
KW - Thirst
KW - Weight Loss
U2 - 10.1079/BJN20031064
DO - 10.1079/BJN20031064
M3 - Journal article
C2 - 15005830
VL - 91
SP - 439
EP - 446
JO - British Journal of Nutrition
JF - British Journal of Nutrition
SN - 0007-1145
IS - 3
ER -
ID: 132054581